Medindia LOGIN REGISTER
Medindia
Advertisement

Anesiva Announces Hiring of Sales Force for FDA-Approved Product Zingo(TM)

Thursday, January 31, 2008 General News
Advertisement
SOUTH SAN FRANCISCO, Calif., Jan. 30 Anesiva,Inc. (Nasdaq: ANSV) today announced that the company has completed the hiringand deployment of its hospital-focused sales force to support the commercialintroduction of Anesiva's FDA-approved Zingo(TM) (lidocaine hydrochloridemonohydrate) powder intradermal injection system, in the second quarter of2008.
Advertisement

"By adding a sales force and sales leadership team with substantialhospital sales experience to our commercial group, we believe we've laid thegroundwork for a successful introduction of Zingo in the second quarter," saidNancy E. Donahue, senior vice president of sales and marketing at Anesiva."Anesiva's representatives will focus on creating demand by informing andeducating nurses and physicians about Zingo. Their initiatives will becomplemented by the efforts of Sagent Pharmaceuticals' representatives, whowill work primarily with hospital pharmacies. These synergistic selling rolesare expected to drive faster inclusion on hospital formularies and salesuptake." Anesiva and Sagent have a co-promotion agreement for Zingo in theUnited States.
Advertisement

The two Anesiva sales directors are Joseph Levato and David Randall. Joeis an award-winning seasoned professional with 17 years industry salesexperience, the past 10 in management. A significant portion of hisexperience is in the hospital marketplace. Joe has managerial depth withstrong skills at building teams, launching new products and exceeding goals.Dave comes to Anesiva from Elan Corporation where he spent 13 years, the pastsix as a manager in the Hospital Specialty Business. During this time, Davecontinued to take on new roles with increasing responsibility and consistentlyexceeded expectations.

Anesiva's 15 Regional Account Managers (RAMs) also have a significantamount of tenure and previous success driving formulary additions and uptakein the hospital market. On average, they have 14 years of selling experience,9 in the hospital arena. The RAMs are located in geographic areas in theUnited States that have significant concentrations of pediatric hospitals.These institutions perform the majority of the 18 million annual peripheralvenous access procedures in children ages three to 18. The RAMs have completedtraining and are now deployed into their territories.

About Zingo

Zingo provides topical, local analgesia to reduce the pain associated withperipheral IV insertions or blood draws, and is FDA-approved for use inchildren three to 18 years of age. Zingo is an easy-to-administer, single-use,needle-free system containing 0.5 mg sterile lidocaine powder. It providesrapid onset of action, allowing intravenous line placement or venipuncture tobegin one to three minutes after administration.

In two pivotal, multicenter, randomized, double-blind, placebo-controlledclinical studies, a total of 1,114 pediatric patients in the U.S., Zingodemonstrated a statistically significant reduction in procedural pain comparedto placebo. In the clinical trials, the most common adverse events wereredness (erythema), red dots (petechiae) and swelling (edema) at the site ofadministration.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to bethe leader in the development and commercialization of novel pharmaceuticalproducts for pain management. The company has one FDA-approved product,Zingo(TM), for the reduction of pain associated with peripheral venous accessprocedures in children ages three to 18. The second product in Anesiva'spipeline, Adlea(TM), has been shown to reduce pain after only a singleadministration for weeks to months in multiple settings in numerous mid-stageclinical trials for site-specific, acute and chronic, moderate-to-severe pain.Anesiva is based in South San Francisco, CA. For more information aboutAnesiva's leadership in the developm
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close